OPDIVO 100 MG
NIVOLUMAB : 10 MG · DIN 02446626 · BRISTOL-MYERS SQUIBB CANADA
Health Canada status: MARKETED
What is OPDIVO?
OPDIVO 100 MG contains NIVOLUMAB : 10 MG. It is listed in the Health Canada Drug Product Database under DIN 02446626, held by BRISTOL-MYERS SQUIBB CANADA, supplied as SOLUTION for INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 23-Oct-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is OPDIVO used for?
Melanoma (unresectable, metastatic, or adjuvant), NSCLC, MPM, RCC, SCCHN, cHL, MSI-H/dMMR Colorectal Cancer, Esophageal/GEJ Cancer, Gastric Cancer, Urothelial Carcinoma, HCC.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02446626 |
|---|---|
| Brand name | OPDIVO |
| Generic / active ingredient | NIVOLUMAB : 10 MG |
| Manufacturer | BRISTOL-MYERS SQUIBB CANADA |
| Strength | 100 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS |
| Schedule | Prescription |
| ATC code | L01FF01 NIVOLUMAB |
| AHFS class | 10:00.00 |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 23-Oct-2015 |
| Original market date | 2015-10-23 00:00:00 |
How is it administered?
Administered as intravenous infusion over 30 minutes. Dosages vary by indication: commonly 240 mg every 2 weeks, 480 mg every 4 weeks, or 1-3 mg/kg depending on monotherapy or combination use.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in the provided summary text, though listed as a section in the table of contents.
How is it supplied?
40 mg and 100 mg single-use vials.
Contraindications
Hypersensitivity to nivolumab or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.
Warnings and precautions
Severe and fatal immune-mediated adverse reactions involving any organ system. Early diagnosis and management essential. Discontinue for severe/life-threatening reactions.
What can be used instead?
Other Canadian products sharing ATC code L01FF01 NIVOLUMAB. 3 of 3 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| OPDIVO | 10 MG | SOLUTION | BRISTOL-MYERS SQUIBB CANADA | MARKETED | DIN 02446634 |
| OPDIVO SC | 120 MG | SOLUTION | BRISTOL-MYERS SQUIBB CANADA | MARKETED | DIN 02557320 |
Who else supplies NIVOLUMAB worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. NIVOLUMAB appears in 38 registered pack listings across 9 markets, published on 7 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.